|Values are valid only on day of printing.|
Evaluating patients with signs and symptoms of a connective tissue disease in whom the test for antinuclear antibodies is positive
SS-A/Ro is an extractable nuclear antigen (ENA) composed of protein antigens of 52 kD and 60 kD combined with cytoplasmic RNA species. SS-A/Ro antibodies occur in patients with several different connective tissue diseases including Sjogren syndrome, an autoimmune disease that involves primarily the salivary and lachrymal glands (up to 90% of cases); lupus erythematosus (LE) (40%-60% of cases); and rheumatoid arthritis. SS-A/Ro antibodies are associated with childhood LE, neonatal LE, and with congenital heart block in infants born to mothers with LE.(1,2) SS-A/Ro antibodies have also been reported to be associated with features of extraglandular inflammation in patients with LE including vasculitis, purpura, cytopenias, and adenopathy.
SS-A/Ro is 1 of 4 autoantigens commonly referred to as extractable nuclear antigens (ENAs). The other ENAs are SS-B/La, RNP, and Sm. Each ENA is composed of 1 or more proteins associated with small nuclear or cytoplasmic RNA species (snRNP) ranging in size from 80 to 350 nucleotides. Antibodies to ENAs are common in patients with connective tissue diseases (systemic rheumatic diseases) including LE, mixed connective tissue disease, Sjogren syndrome, scleroderma (systemic sclerosis), and polymyositis/dermatomyositis.
See Connective Tissue Disease Cascade (CTDC) in Special Instructions and Optimized Laboratory Testing for Connective Tissue Diseases in Primary Care: The Mayo Connective Tissue Diseases Cascade in Publications.
<1.0 U (negative)
> or =1.0 U (positive)
Reference values apply to all ages.
A positive result for SS-A/Ro antibodies is consistent with connective tissue disease, including Sjogren syndrome, lupus erythematosus (LE), or rheumatoid arthritis.
A positive result for SS-A/Ro antibodies in a woman with LE prior to delivery indicates an increased risk of congenital heart block in the neonate.
Testing for SS-A/Ro antibodies is not useful in patients without demonstrable antinuclear antibodies.
1. Homburger H, Larsen S: Detection of specific antibodies. In Clinical Immunology: Principles and Practice. First edition. Edited by R Rich, T Fleisher, B Schwartz, et al. St. Louis, Mosby-Year Book, 1996, pp 2096-2109
2. Kotzin B, West S: Systemic lupus erythematosus. In Clinical Immunology Principles and Practice. Second edition. Edited by R Rich, T Fleisher, W Shearer, et al. St. Louis, Mosby-Year Book 2001, pp 60.1-60.24